BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
BCI
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 25, 2026
See today's BioWorld
Home
» Gilead's $11B Pharmasset Buy Validates Nuc Prodrug Strategy
To read the full story,
subscribe
or
sign in
.
Gilead's $11B Pharmasset Buy Validates Nuc Prodrug Strategy
Nov. 22, 2011
By
Marie Powers
Thanksgiving came early for Pharmasset Inc. with the news that Gilead Sciences Inc. will gobble it up in a deal valued at $11 billion.
BioWorld